Insys Therapeutics (NASDAQ:INSY)‘s stock had its “hold” rating reissued by stock analysts at Oppenheimer in a research note issued to investors on Sunday, November 12th.
Other equities analysts have also issued research reports about the company. BidaskClub upgraded Insys Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 26th. Piper Jaffray Companies set a $10.00 price target on Insys Therapeutics and gave the stock a “hold” rating in a research note on Wednesday, July 26th. Zacks Investment Research lowered Insys Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Royal Bank Of Canada dropped their price target on Insys Therapeutics from $16.00 to $14.00 and set an “outperform” rating on the stock in a research note on Friday, August 4th. Finally, TheStreet lowered Insys Therapeutics from a “c-” rating to a “d+” rating in a research note on Monday, August 21st. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $9.38.
Insys Therapeutics (INSY) traded down $0.05 on Friday, reaching $5.25. The company’s stock had a trading volume of 385,976 shares, compared to its average volume of 764,310. Insys Therapeutics has a 52 week low of $4.10 and a 52 week high of $15.02.
About Insys Therapeutics
Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.
Receive News & Ratings for Insys Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc. and related companies with our FREE daily email newsletter.